Status:

UNKNOWN

Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study

Lead Sponsor:

Chiang Mai University

Conditions:

Acute Heart Failure

Acute Kidney Injury

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study aims to demonstrate the efficacy of sequential nephron blockade by adding hydrochlorothiazide or spironolactone on intravenous furosemide compared to intravenous furosemide alone in the tre...

Detailed Description

This study is a randomised, double-blinded, double-dummy, placebo-controlled study to demonstrate the efficacy of oral hydrochlorothiazide or spironolactone in combination with intravenous furosemide ...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Diagnosis of acute heart failure which is defined by 2 of the 3 following features: ≥2+ leg edema, jugular venous pressure \>10 cm from physical examination or central venous pressure \>10 mmHg, and bilateral pulmonary edema or bilateral pleural effusion from chest radiography
  • Patients consent to participate into the study

Exclusion

  • Patients who receive furosemide ≥500 mg/day or hydrochlorothiazide ≥100 mg/day or spironolactone ≥100 mg/day or tolvaptan of any doses
  • Patients who have systolic blood pressure \<100 mmHg or who need vasoactive drugs inotropic agents (except dobutamine)
  • Patients with intravascular volume depletion from clinical evaluation
  • Patients with chronic kidney disease stage 5 (estimated glomerular filtration rate \<15 ml/min/1.73 m2) or patients who receive maintenance dialysis
  • Patients who require renal replacement therapy at the time of admission
  • Patients whom diagnosed hypertrophic obstructive cardiomyopathy, severe valvular stenosis or complex congenital heart disease
  • Patients with sepsis or systemic infection
  • Pregnant women
  • Patients who have history of furosemide, spironolactone or hydrochlorothiazide allergy

Key Trial Info

Start Date :

August 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04465123

Start Date

August 13 2020

End Date

December 31 2022

Last Update

August 18 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chiang Mai University Hospital, Faculty of Medicine, Chiang Mai University

Chiang Mai, Thailand, 50200